New Century Financial Group’s Vertex Pharmaceuticals VRTX Stock Holding History

New Century Financial Group’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-967	Closed	-$469K	–	168
2025 Q1	$469K	Buy	967 +140	+17%	+$65.2K	0.54%	65
2024 Q4	$337K	Sell	827 -62	-7%	-$28.7K	0.14%	191
2024 Q3	$413K	Sell	889 -298	-25%	-$143K	0.15%	177
2024 Q2	$556K	Sell	1,187 -349	-23%	-$151K	0.24%	124
2024 Q1	$642K	Sell	1,536 -230	-13%	-$97.2K	0.44%	75
2023 Q4	$719K	Buy	+1,766	New	+$652K	0.62%	54

Other funds holding VRTX

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

New Century Financial Group's VRTX Position: Q2 2025 in Review

New Century Financial Group sold out of Vertex Pharmaceuticals (VRTX) in Q2 2025, closing a stake of 967 shares — an estimated $469K sold.

New Century Financial Group first reported a position in VRTX in Q4 2023 and held it in 6 quarters. The position peaked at $719K in Q4 2023. 1,559 funds tracked by Wall St. Rank hold VRTX as of Q2 2025.

New Century Financial Group reported no remaining Vertex Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
New Century Financial Group sold 967 Vertex Pharmaceuticals shares in Q2 2025, an estimated $469K.
New Century Financial Group first reported a position in Vertex Pharmaceuticals in Q4 2023 and held it in 6 quarters.
New Century Financial Group's Vertex Pharmaceuticals position peaked at $719K in Q4 2023.
1,559 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2025.

Based on New Century Financial Group's 13F filing for Q2 2025, filed 21 Jul 2025.